ClinicalTrials.gg
RecruitingNCT06266182Updated May 16, 2024

The Effect of an Online ACT Intervention on Meaning-Making Process in Cancer Patients Following Hematopoietic Cell Transplantation

An interventional study of Acceptance and Commitment Therapy and Education in Hematopoietic Cell Transplantation Recipient and Acceptance and Commitment Therapy, sponsored by University of Social Sciences and Humanities, Warsaw. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by University of Social Sciences and Humanities, Warsaw · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial aimed to test internet-based Acceptance and Commitment Therapy (ACT) intervention to induce a meaning-making process in cancer patients following hematopoietic cell transplantation (HCT). ACT includes identifying personal values and engaging in activities consistent with these values, developing acceptance, as well as focusing on the present moment or performing activities with greater awareness. In total, 192 patients following the first (autologous or allogeneic) HCT will be randomly assigned in equal numbers to either the ACT intervention or an education session. Participants in both conditions will take part in 14-day training (about 5-10 minutes a day). The outcomes will be measured at baseline, during the intervention, immediately, 1 month, and 3 months after the intervention. Moreover, 6-9 additional participants will be randomly assigned to pre-intervention measurement length (1-3 weeks) before completing ACT intervention, followed by 7-day observations at the 2nd and 3rd post-intervention measure. The researchers hypothesized that ACT intervention would foster a meaning-making process and thus reduce distress induced by the discrepancy between global and situational meaning as compared to education.

Read the detailed description

This trial evaluates the feasibility, acceptability, and preliminary efficacy of self-help internet-based Acceptance and Commitment Therapy (ACT) intervention on meaning-related distress as well as secondary outcomes in patients following hematopoietic cell transplantation (HCT). Randomized controlled trial (RCT) will be enhanced with a single-case experimental design (SCED).

Recruitment will take place at a single center, after elective admission to the bone marrow transplantation and oncohematology unit due to HCT before the start of conditioning treatment. Recruitment will take place on average on the 2nd day after admission. Every two days, the transplant coordinator and physician (members of the research team) will review the lists of patients enrolled for HCT. Those who meet the inclusion criteria will be initially informed of the purpose of the study and invited for an extensive briefing by a recruiter (member of the research team). Patients will also be allowed to ask any remaining questions about the aim of the study and the study procedures. After receiving an extensive briefing, all patients who give written informed consent will proceed with baseline. Data will be collected via a self-reported survey on a mobile device. Clinical data will be obtained from the medical records. All participants will receive written user instructions for the daily sessions and measurements.

In RCT, participants will be randomly assigned in a double-blinded manner to ACT intervention and education conditions at a ratio of 1:1 by a trial coordinator (member of the research team). Randomization will be stratified by type of transplant. Participants and researchers analyzing data will be blind to the allocation of the participants to the conditions. Participants allocated to the ACT intervention will receive online ACT-based intervention within 14 days after hospital discharge. Each day's intervention will consist of an educational and practical part (standard ACT activity) followed by a debrief. On some days, participants will also receive additional exercise (optional). The whole intervention will be tailored to the context of the disease and treatment. During the same period, participants allocated to the education will receive an online guide to post-HCT recommendations. The intervention/education will be discontinued by participants at any time without any negative consequences. During the intervention/education, participants will fill in a short questionnaire assessing potential mediator variables each day, at the beginning of every online session. Participants will receive daily reminders about the intervention/education. Also, direct technical support will be available 24/7. If participants fail to complete study assessments, motivational reminders will be sent by email. If participants drop out or stop using the intervention, they will be asked for the reason(s) why they decided to quit the intervention and/or study.

In SCED, all participants will take part in the online ACT intervention and daily surveys at the 2nd and 3rd post-intervention assessments.

Feasibility will be examined via attrition and adherence rates, as well as questions about intervention engagement. Acceptability will be measured by intervention satisfaction and evaluation (attractiveness and easiness).

02

Conditions studied

  • Hematopoietic Cell Transplantation Recipient
  • Acceptance and Commitment Therapy

Keywords

  • cancer patients
  • hematopoietic cell transplantation
  • ACT-based intervention
  • web-based intervention
  • meaning-making
  • subjective well-being
  • psychological flexibility
  • randomized controlled trial
  • single-case experimental design
03

In context

Lead sponsor

University of Social Sciences and Humanities, Warsaw is the lead sponsor of 25 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Qualification for the first or allogeneic HCT due to hematologic or solid tumors
  • Age ≥ 18 years
  • Signed written
  • Ability to read and write in Polish
  • Daily access to the Internet by computer and/or mobile device

Exclusion criteria

Exclusion Criteria:

  • Major psychiatric or cognitive disorder that would impede providing and study participation
  • Inability to cooperate and give informed consent
  • Hearing, seeing, or movement impairment that precludes participation
  • Current participation in any form of psychotherapy
  • No access to the Internet
  • No access to a computer and/or mobile device
  • Inability to use a computer and/or mobile device and the Internet
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    ACT intervention

    Participants in the ACT intervention arm will learn new adaptive ways to cope with difficulties (including difficult thoughts or feelings).

    Behavioral: Acceptance and Commitment Therapy

  • Other
    Education

    Participants in the Education arm will become familiar with post-HCT recommendations. This will be a minimally enhanced usual care.

    Behavioral: Education

Interventions

  • BehavioralAcceptance and Commitment Therapy

    ACT intervention will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive a web-based intervention consisting of educational and practical tasks/activities. Participants will learn to recognize moments of choice (actions that lead towards values or away from them) and to use attention flexibly to free themselves from the power of thoughts, to open up and accept emotions, and to be able to determine what is important and take action in line with values. All of the tasks will be available in written form and audio. The ACT intervention is built from standard ACT exercises.

    Also known as: ACT-based intervention, ACT

  • BehavioralEducation

    Education will start on the second day after hospital discharge and will take 14 days (+ day 0 with organizational information). Each day, participants will receive information about post-transplant prescriptions along with exercises to support the implementation. Participants will learn about nutrition, personal hygiene, preventing infections, coping with fatigue, resuming activity, rest and sleep, engaging in social interactions, and sexual health. The content is prepared based on available guides for HCT recipients.

06

What researchers measure

Primary outcomes

  1. Distress (Global Meaning Violation Scale; GMVS)

    The GMVS measures meaning-related distress. It is a 12-item questionnaire (from the original, the item "health" was removed due to the context of the study) that assesses belief (5 items) and goal violations (7 items) in response to stressors on a 5-point scale ranging from 1 (not at all) to 5 (very much). The overall score is calculated by summing the scores of all 12 items, with a possible range of 12-60. Higher scores indicate greater meaning-related distress (greater global meaning violation).

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

Secondary outcomes

  1. Illness perception (Brief-Illness Perception Questionnaire; B-IPQ)

    The B-IPQ measures cognitive and emotional representations of illness. It is an 8-item questionnaire that assesses cognitive illness representation, emotional illness representation, and illness comprehensibility representation on a 0-10 point scale. The total score is calculated by summing the scores of all 8 items, with a possible range of 0-80. Higher scores indicate more threatening perception of the illness.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  2. Global meaning (Meaning in Life Questionnaire; MLQ)

    The MLQ measures meaning in life. It is a 10-item questionnaire that assesses the Presence of meaning in life and the Searches for meaning in life on a 7-point scale ranging from 1 (absolutely untrue) to 7 (absolutely true). The subscale scores are calculated by summing the scores of relevant items (5 per subscale), with a possible range of 5-35. Higher scores indicate a greater Presence of meaning in life and Search for meaning in life, respectively.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  3. Psychological flexibility (Comprehensive Assessment of Acceptance and Commitment Therapy Processes-9; CompACT-9)

    The CompACT-9 measures psychological flexibility. It is a 9-item questionnaire that assesses Openness to Experience, Behavioral Awareness, and Valued Action on a 7-point scale ranging from 0 (strongly disagree) to 6 (strongly agree). The overall score is calculated by summing the scores of all 9 items, with a possible range of 0-36. Higher scores indicate higher psychological flexibility (greater openness to experience and willingness to experience internal events such as thoughts, feelings, sensations, etc. without trying to control or avoid them; greater behavioral awareness and mindful attention to current actions; greater engagement in valued actions and meaningful activity).

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  4. Coping self-efficacy (Coping Self-Efficacy Scale; CSE - selected items)

    The CSE measures a perceived self-efficacy for coping with challenges and threats. This study used 6 items tailored to the context of the study (2 per subscale: Problem-focused Coping, Emotion-focused Coping, and Social Support Coping) assessed on a 5-point scale ranging from 1 (not at all) to 5 (strongly). The overall score is calculated by summing the scores of all 6 items, with a possible range of 6-30. Higher scores indicate greater coping self-efficacy.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  5. Deliberate meaning-making (Core Beliefs Inventory; CBI)

    The CBI is a 10-item questionnaire that assesses deliberate meaning-making coping on a 6-point scale ranging from 0 (not at all) to 5 (to a very degree). The total score is calculated by summing the scores of all 10 items, with a possible range of 0-45. Higher scores indicate greater deliberate searching for meaning.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  6. Automatic meaning-making (Event-Related Rumination Inventory; ERRI - intrusive ruminations subscale)

    The intrusive ruminations subscale of the ERRI measures automatic meaning-making coping. It is a 10-item subscale that assesses intrusive ruminations on a 4-point scale ranging from 0 (not at all) to 3 (often). The total score is calculated by summing the scores of all 10 items, with a possible range of 0-30. Higher scores indicate greater automatic searching for meaning.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  7. Post-traumatic growth (the "current standing" Post-Traumatic Growth Inventory-Short Form; C-PTGI-SF )

    The C-PTGI-SF measures psychological well-being in cross-sectional assessment, as well as posttraumatic growth (element of meanings made) in multiple assessments. It is a 10-item questionnaire that assesses psychological well-being on a 6-point scale ranging from 0 (not at all) to 5 (to a very great degree). The total score is calculated by summing the scores of all 10 items, with a possible range of 0-50. Higher scores indicate better well-being.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  8. Meanings made (Meaning of Loss Codebook; MLC)

    The MLC evaluates meanings made. It is a 3-item tool that assesses sense made, benefit finding, and sense of identity change on a 5-point scale ranging from 1 (not at all) to 5 (to a very great degree). The overall score is calculated by summing the scores of all 3 items, with a possible range of 3-15. Higher scores indicate greater meanings made.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  9. Anxiety and depressive symptoms (Patient Health Questionnaire-4; PHQ-4)

    The PHQ-4 is a 4-item questionnaire that assesses symptoms of anxiety (2 items) and depression (2 items) on a 4-point scale ranging from 0 (not at all) to 3 (nearly every day). The subscale scores are calculated by summing the scores of 2 items, with a possible range of 0-6. Higher scores indicate higher levels of anxiety and depression symptoms, respectively. The total PHQ-4 score complements the subscale scores as an overall measure of symptom burden, as well as functional impairment and disability.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  10. Loneliness (The Revised UCLA Loneliness Scale; R-UCLA - selected items)

    The R-UCLA measures perceived social isolation. This study used 5 items that assess the emotional and social aspects of loneliness on a 4-point scale ranging from 1 (never) to 4 (often or always). The total score is calculated by summing the scores of all 5 items, with a possible range of 5-20. Higher scores indicate greater loneliness.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  11. Loneliness (the Community Life Survey)

    A direct question about loneliness from the Community Life Survey is used. The statement is assessed on a 4-point scale ranging from 1 (never) to 4 (often or always). A higher score indicates greater loneliness.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  12. Health-related quality of life (Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer; EORTC QLQ-C3)

    The EORTC QLQ-C30 measures the health-related quality of life of cancer patients. It is a 30-item questionnaire that assesses physical, role, social, emotional, and cognitive functioning, as well as various symptoms, financial impact, and global quality of life. Twenty-eight items are rated on a 4-point scale ranging from 1 (not at all) to 4 (very much), while 2 items are rated on a 7-point scale ranging from 1 (very poor) to 7 (excellent). The overall score is calculated by summing the scores of all items, with a possible range of 0-100. Higher scores indicate better function and a higher quality of life.

    Time frame: Change from baseline to immediately, 1 month and 3 months after intervention

  13. Daily subjective health (Daily Subjective Health Scale)

    Daily subjective health is measured by a single-item statement "Generally, I can say my health today was ..." on a 5-point scale ranging from 1 (bad) to 5 (excellent). Higher scores indicate greater daily physical health.

    Time frame: RCT: day-by-dy for 14 days during the intervention. SCED: for 7-21 days before intervention, day-by-dy for 14 days during the intervention, for 7 days immediately, 1 month, and 3 months after intervention

  14. Daily affect (Daily Positive and Negative Affect Scale)

    The Daily Positive and Negative Affect Scale is a 4-item questionnaire that consists of two positive (happy, cheerful) and two negative adjectives (sad, gloomy) rated on a 5-point scale ranging from 1 (not at all) to 5 (to a very great degree). The subscale scores are calculated by summing the scores of relevant items, with a possible range of 2-10. Higher scores indicate higher daily positive or negative affect.

    Time frame: RCT: day-by-dy for 14 days during the intervention. SCED: for 7-21 days before intervention, day-by-dy for 14 days during the intervention, for 7 days immediately, 1 month, and 3 months after intervention

  15. Daily meaning-making (Event-Related Rumination Inventory-daily form; ERRI-daily form)

    The ERRI-daily form measures deliberate and automatic meaning-making coping. It is a 4-item tool that assesses deliberate and intrusive ruminations on a 4-point scale ranging from 0 (not at all) to 3 (to a very great degree). The subscale scores are calculated by summing the scores of relevant items (2 per subscale), with a possible range of 0-6. Higher scores indicate greater deliberate or automatic searching for meaning.

    Time frame: RCT: day-by-dy for 14 days during the intervention. SCED: for 7-21 days before intervention, day-by-dy for 14 days during the intervention, for 7 days immediately, 1 month, and 3 months after intervention

  16. Daily meanings made (Meaning of Loss Codebook-daily form; MCL-daily form)

    The MLC-daily form measures daily meanings made. It is a 3-item tool that assesses daily sense made, benefit finding, and sense of identity change on a 5-point scale ranging from 1 (not at all) to 5 (to a very great degree). The overall score is calculated by summing the scores of all 3 items, with a possible range of 3-15. Higher scores indicate greater daily meanings made.

    Time frame: RCT: day-by-dy for 14 days during the intervention. SCED: for 7-21 days before intervention, day-by-dy for 14 days during the intervention, for 7 days immediately, 1 month, and 3 months after intervention

  17. Daily psychological flexibility (Comprehensive Assessment of Acceptance and Commitment Therapy Processes-daily form; CompACT-daily form)

    The CompACT-daily form is a 4-item tool that assesses daily psychological flexibility (i.e. daily Openness to experience - 2 items, daily Behavioral awareness - 1 item, and daily Valued action - 1 item) on a 7-point scale ranging from 0 (strongly disagree) to 6 (strongly agree). The overall score is calculated by summing the scores of all 4 items, with a possible range of 0-24. Higher scores indicate higher daily psychological flexibility (i.e. greater daily openness to experience and willingness to experience internal events such as thoughts, feelings, sensations, etc. without trying to control or avoid them; greater daily behavioral awareness and mindful attention to current actions; greater daily engagement in valued actions and meaningful activity).

    Time frame: RCT: day-by-dy for 14 days during the intervention. SCED: for 7-21 days before intervention, day-by-dy for 14 days during the intervention, for 7 days immediately, 1 month, and 3 months after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The full protocol, dataset, statistical codes, and outputs will be made available at the Open Science Framework (OSF). Anonymized participant-level datasets will be publicly available, however, without demographics and clinical data due to privacy or ethical restrictions (the possibility of identification of participants). The data will be stored for at least 5 years after the end of the project unless other regulations lengthen the need to store the data or it is not necessary due to other reasons (e.g. documentation of research results).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Beginning 3 months after publication without an end date.

Access criteria: All those who will have an open link.

Data sharing details ↗ · osf.io

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06266182
Lead sponsor
University of Social Sciences and Humanities, Warsaw
Collaborators
National Science Centre, Poland
Responsible party
Aleksandra Kroemeke (PhD, Associate professor, University of Social Sciences and Humanities, Warsaw) — Principal investigator
First posted
Feb 20, 2024
Start date
Mar 6, 2024
Primary completion
Dec 2025 (estimated)
Completion
Apr 2026 (estimated)
Last update
May 16, 2024

Study contacts

Aleksandra Kroemeke, PhD
Contact
akroemeke@swps.edu.pl
011 48 225179824
Aleksandra Kroemeke, PhD
principal investigator · SWPS University (University of Social Sciences and Humanities)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion